Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: A randomized crossover controlled trial

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 4, 2013, Pages 297-305

  Haidar, Ahmad ^a,b   Legault, Laurent ^c   Dallaire, Maryse ^a   Alkhateeb, Ammar ^a   Coriati, Adèle ^a   Messier, Virginie ^a   Cheng, Peiyao ^e   Millette, Maude ^c   Boulet, Benoit ^b   Rabasa Lhoret, Rémi ^a,d  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN ASPART; RECOMBINANT GLUCAGON;

ADULT; ALGORITHM; ARTIFICIAL PANCREAS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTERMETHOD COMPARISON; MALE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 84875188726     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121265     Document Type: Article

References (21)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
2. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
3. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-67.
4. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45: 937-48.
5. Hypoglycemia in the Diabetes Control and Complications Trial; The Diabetes Control and Complications Trial Research Group. Diabetes 1997;46:271-86.
6. Choudhary P, Geddes J, Freeman JV, et al. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: No identifiable differences using continuous glucose monitoring. Diabet Med 2010;27:666-72.
7. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care 2010; 33: 1004-8.
8. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-20.
9. Hovorka R. Closed-loop insulin delivery: From bench to clinical practice. Nat Rev Endocrinol 2011;7:385-95.
10. Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: Modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012;61:2230-7.
11. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: Crossover randomised controlled studies. BMJ 2011; 342: D1855.
12. Shichiri M, Kawamori R, Yamasaki Y, et al. Wearable artificial endocrine pancreas with needle-type glucose sensor. Lancet 1982; 2:1129-31.
13. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-7.
14. El-Khatib FH, Russell SJ, Nathan DM, et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2:27ra27.
15. Chico A, Vidal-Rios P, Subira M, et al. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153-7.
16. Buckingham B, Block J, Burdick J, et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005;7:440-7.
17. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: Summary of the results. J Diabetes Sci Technol 2010;4:1374-81.
18. Atlas E, Nimri R, Miller S, et al. MD-logic artificial pancreas system: A pilot study in adults with type 1 diabetes. Diabetes Care 2010;33:1072-6.
19. Russell SJ, El-Khatib FH, Nathan DM, et al. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012;35:2148-55.
20. Steiner SS, LiM, Hauser R, et al. Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol 2010; 4: 1332-7.
21. Ward WK, Massoud RG, Szybala CJ, et al. In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: Lack of cytotoxicity and preservation of hyperglycemic effect. J Diabetes Sci Technol 2010;4:1311-21.